HIV-1 Infection Equipment & Supplies

A rapid, 20 minute in vitro immunoassay that differentiates recent from long-term HIV-1 infections for real time surveillance of new HIV-1 infections and the estimation of HIV-1 incidence rates in a population.* The assay can be used with blood (both venous and ...

The Maxim HIV-1 Limiting Antigen-Avidity EIA is an in-vitro quantitative limiting antigen (LAg) avidity enzyme immunoassay for distinguishing recent HIV-1 infections from those which are long-term. Persons with recently acquired HIV-1 infections typically exhibit ...

An in vitro single well quantitative limiting antigen avidity enzyme immunoassay for distinguishing recent HIV-1 infections from those which are long-term. Intended for use with liquid serum or plasma specimens. ...

This kit is intended as an aid in the diagnosis of infection with HIV-1 and/or HIV-2, including acute (primary) HIV-1 infection. The assay may also be used as an aid in the diagnosis of infection with HIV-1 and/or ...

DELSTRIGO (doravirine, lamivudine, and tenofovir disoproxil fumarate) tablets, for oral use Initial U.S. Approval: ...

To develop an all-injectable long-acting HIV therapy, Frontier Biotech has designed and developed a combination regimen of Albuvirtide (ABT) and 3BNC117, a recombinant fully human monoclonal antibody with broadly neutralizing effects to HIV-1 ...

HIV-1 is a virus that attacks the immune system in humans. It targets CD4+ T cells (a type of immune cell) that are crucial for fighting off infections. If left untreated, the virus can impair the immune system’s ability to fight off other infections and diseases. ...

Latently infected cells remain a permanent source of viral reactivation. For this reason, the eradication of viral reservoirs is at present the major goal for HIV-1 therapeutics. ...

A Whole Blood Assay to assess Individual Patient Responses to Novel Antiviral Therapeutics. While combination anti-retroviral drugs (cART) can control active HIV-1 virus replication, they are not “curative”. Rather, these drugs are required life-long. Developing new therapeutic strategies that can reduce or clear persistent, underlying sources of ...

Biotron is developing novel small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and ...